BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19344229)

  • 21. Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia.
    Dayer-Berenson L; Finckenor M
    Postgrad Med; 2014 May; 126(3):126-34. PubMed ID: 24918798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.
    Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):515-25. PubMed ID: 22432790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
    Rosenstock J; Truitt KE; Baz-Hecht M; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 Dec; 46(13):943-9. PubMed ID: 25054436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.
    Rosenson RS; Rigby SP; Jones MR; Chou HS
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):229-36. PubMed ID: 24710760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
    Hunninghake D; Insull W; Toth P; Davidson D; Donovan JM; Burke SK
    Atherosclerosis; 2001 Oct; 158(2):407-16. PubMed ID: 11583720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
    Rigby SP; Handelsman Y; Lai YL; Abby SL; Tao B; Jones MR
    Endocr Pract; 2010; 16(1):53-63. PubMed ID: 19789153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Ooi CP; Loke SC
    Diabet Med; 2014 Jan; 31(1):2-14. PubMed ID: 24024701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol).
    Mazze RS; Strock ES; Monk AM; Murphy MM; Xi M; Bergenstal RM
    Endocr Pract; 2013; 19(2):275-83. PubMed ID: 23598534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.
    Vega GL; Dunn FL; Grundy SM
    Am J Cardiol; 2011 Oct; 108(8):1129-35. PubMed ID: 21813109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
    Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
    Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of colesevelam in type 2 diabetes mellitus.
    Brunetti L; Campbell RK
    J Pharm Pract; 2011 Aug; 24(4):417-25. PubMed ID: 21813819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of colesevelam in combination lipid-lowering therapy.
    Jones MR; Nwose OM
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):315-23. PubMed ID: 23913404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colesevelam for type 2 diabetes mellitus.
    Ooi CP; Loke SC
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD009361. PubMed ID: 23235674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Elkeles RS
    Diabet Med; 2014 Jul; 31(7):880. PubMed ID: 24588426
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of colesevelam HCl in patients with type 2 diabetes mellitus: combining glucose- and lipid-lowering effects.
    Goldfine AB; Fonseca VA
    Postgrad Med; 2009 May; 121(3 Suppl 1):13-8. PubMed ID: 19494473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.
    Rivers SM; Kane MP; Busch RS; Bakst G; Hamilton RA
    Endocr Pract; 2007; 13(1):11-6. PubMed ID: 17360295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.